Maya Gottfried

Research interests

Publications

• Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer

  Journal of Clinical Oncology · 2024 · https://doi.org/10.1200/jco.23.02747

• Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study

  Annals of Oncology · 2022 · https://doi.org/10.1016/j.annonc.2022.05.519

• Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%

  Journal of Clinical Oncology · 2021 · https://doi.org/10.1200/jco.21.00174

• Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage–SCLC: Results From the Phase 3 MERU Study

  Journal of Thoracic Oncology · 2021 · 10.1016/j.jtho.2021.03.012

• Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study

  Journal of Clinical Oncology · 2020 · https://doi.org/10.1200/jco.20.00793

• Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater

  Journal of Clinical Oncology · 2019 · https://doi.org/10.1200/jco.18.00149

• Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies

  Journal of Thoracic Oncology · 2019 · https://doi.org/10.1016/j.jtho.2019.12.109

• Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study

  Journal of Clinical Oncology · 2019 · https://doi.org/10.1200/jco.19.02105

• Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158.

  Journal of Clinical Oncology · 2018 · 10.1200/jco.2018.36.15_suppl.8506

• Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial

  The Lancet Oncology · 2017 · https://doi.org/10.1016/s1470-2045(17)30690-3

• Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2016 · https://doi.org/10.1056/nejmoa1606774

• Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

  Annals of Oncology · 2015 · 10.1093/annonc/mdv597

• Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

  The Lancet Oncology · 2014 · https://doi.org/10.1016/s1470-2045(13)70586-2

• Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Gemcitabine/Cisplatin Alone or With Sorafenib for the First-Line Treatment of Advanced, Nonsquamous Non–Small-Cell Lung Cancer

  Journal of Clinical Oncology · 2012 · https://doi.org/10.1200/jco.2011.39.7646

• Vandetanib Plus Pemetrexed for the Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer: A Randomized, Double-Blind Phase III Trial

  Journal of Clinical Oncology · 2011 · https://doi.org/10.1200/jco.2010.29.5717

• Phase III Comparative Study of High-Dose Cisplatin Versus a Combination of Paclitaxel and Cisplatin in Patients With Advanced Non–Small-Cell Lung Cancer

  Journal of Clinical Oncology · 2000 · https://doi.org/10.1200/jco.2000.18.19.3390

• Activity of gemcitabine in patients with non-small cell lung cancer: A multicentre, extended phase II study

  European Journal of Cancer · 1996 · https://doi.org/10.1016/0959-8049(95)00444-0

Current projects

No projects listed.